359 results on '"Piersma, D"'
Search Results
2. Health-state utilities in long-term advanced melanoma survivors comparable with the general population
- Author
-
Egeler, M. D., van de Poll-Franse, L. V., Tissier, R., Rogiers, A., Boers-Sonderen, M. J., van den Eertwegh, A. J., Hospers, G. A., de Groot, J. W. B., Aarts, M. J. B., Kapiteijn, E., Piersma, D., Vreugdenhil, G., van der Veldt, A. A., Suijkerbuijk, K. P. M., Neyns, B., Janssen, K. J., Blank, C. U., Retèl, V. P., and Boekhout, A. H.
- Published
- 2023
- Full Text
- View/download PDF
3. Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma
- Author
-
van Duin, I.A.J., Schuiveling, M., ter Maat, L.S., Veta, M., van Eijs, M.J.M., Verheijden, R.J., van den Berkmortel, F.W.P.J., Boers-Sonderen, M.J., Hospers, G.A.P., Labots, M., de Groot, J.W.B., Kapiteijn, E., Piersma, D., Vreugdenhil, G., Westgeest, H., Schrader, A.M.R., van Diest, P.J., Blokx, W.A.M., and Suijkerbuijk, K.P.M.
- Published
- 2024
- Full Text
- View/download PDF
4. Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry
- Author
-
Özkan, A., Kapiteijn, E., van den Bos, F., Aarts, M.J.B., van den Berkmortel, F.W.P.J., Blank, C.U., Bloem, M., Blokx, W.A.M., Boers-Sonderen, M.J., Bonenkamp, J.J., van den Eertwegh, A.J.M., de Groot, J.W.B., Haanen, J.B., Holtslag, C.E., Hospers, G.A.P., Piersma, D., van Rijn, R.S., Stevense-den Boer, A.M., Suijkerbuijk, K.P.M., van der Veldt, A.A.M., Vreugdenhil, G., Wouters, M.W.J.M., Portielje, J.E.A., and de Glas, N.A.
- Published
- 2024
- Full Text
- View/download PDF
5. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
- Author
-
Franken, M.G., Leeneman, B., Aarts, M.J.B., van Akkooi, A.C.J., van den Berkmortel, F.W.P.J., Boers-Sonderen, M.J., van den Eertwegh, A.J.M., de Groot, J.W.B., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., van der Veldt, A.A.M., Westgeest, H.M., Wouters, M.W.J.M., Haanen, J.B.A.G., and Uyl-de Groot, C.A.
- Published
- 2021
- Full Text
- View/download PDF
6. Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study
- Author
-
Maat, L.S. Ter, primary, Van Duin, I.A.J., additional, Verheijden, R.J., additional, Moeskops, P., additional, Verhoeff, J.J.C., additional, Elias, S.G., additional, van Amsterdam, W.A.C., additional, Burgers, F.H., additional, Van den Berkmortel, F.W.P.J., additional, Boers-Sonderen, M.J., additional, Boomsma, M.F., additional, De Groot, J.W., additional, Haanen, J.B.A.G., additional, Hospers, G.A.P., additional, Piersma, D., additional, Vreugdenhil, G., additional, Westgeest, H.M., additional, Kapiteijn, E., additional, Labots, M., additional, Veldhuis, W.B., additional, Van Diest, P.J., additional, De Jong, P.A., additional, Pluim, J.P.W., additional, Leiner, T., additional, Veta, M., additional, and Suijkerbuijk, K.P.M., additional
- Published
- 2024
- Full Text
- View/download PDF
7. Seasonal variation of anti-PD-1 outcome in melanoma—Results from a Dutch patient cohort
- Author
-
Borgers, J. S.W., Burgers, F. H., Schina, A., Van Not, O. J., van den Eertwegh, A. J.M., Blank, C. U., Aarts, M. J.B., van den Berkmortel, F. W.P.J., de Groot, J. W.B., Hospers, G. A.P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Boer, A. M.Stevense den, van der Veldt, A. A.M., Vreugdenhil, G., Boers-Sonderen, M. J., Wouters, M. W.J.M., Suijkerbuijk, K. P.M., van Thienen, J. V., Haanen, J. B.A.G., Borgers, J. S.W., Burgers, F. H., Schina, A., Van Not, O. J., van den Eertwegh, A. J.M., Blank, C. U., Aarts, M. J.B., van den Berkmortel, F. W.P.J., de Groot, J. W.B., Hospers, G. A.P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Boer, A. M.Stevense den, van der Veldt, A. A.M., Vreugdenhil, G., Boers-Sonderen, M. J., Wouters, M. W.J.M., Suijkerbuijk, K. P.M., van Thienen, J. V., and Haanen, J. B.A.G.
- Abstract
Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long-term) benefit from these treatments. There is evidence that the exposome, an accumulation of host-extrinsic factors including environmental influences, could impact ICI response. Recently, a survival benefit was observed in patients with BRAF wild-type melanoma living in Denmark who initiated immunotherapy in summer as compared to winter. As the Netherlands lies in close geographical proximity to Denmark and has comparable seasonal differences, a Dutch validation cohort was established using data from our nationwide melanoma registry. In this study, we did not observe a similar seasonal difference in overall survival and are therefore unable to confirm the Danish findings. Validation of either the Dutch or Danish findings in (combined) patient cohorts from other countries would be necessary to determine whether this host-extrinsic factor influences the response to ICI-treatment.
- Published
- 2024
8. Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort
- Author
-
Cancer, MS Medische Oncologie, Infection & Immunity, Borgers, J S W, Burgers, F H, Schina, A, Van Not, O J, van den Eertwegh, A J M, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Boer, A M Stevense-den, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Wouters, M W J M, Suijkerbuijk, K P M, van Thienen, J V, Haanen, J B A G, Cancer, MS Medische Oncologie, Infection & Immunity, Borgers, J S W, Burgers, F H, Schina, A, Van Not, O J, van den Eertwegh, A J M, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Boer, A M Stevense-den, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Wouters, M W J M, Suijkerbuijk, K P M, van Thienen, J V, and Haanen, J B A G
- Published
- 2024
9. A prediction model for response to immune checkpoint inhibition in advanced melanoma
- Author
-
Duin, I.A.J. van, Verheijden, R.J., Diest, P.J. van, Blokx, W.A.M., El-Sharouni, M.A., Verhoeff, J.J., Leiner, T., Eertwegh, A.J.M. van den, Groot, J.W.B. de, Not, O.J. van, Aarts, M.J.B., Berkmortel, F. van den, Blank, C.U., Haanen, J., Hospers, G.A.P., Piersma, D., Rijn, R.S. van, Veldt, A.A. van der, Vreugdenhil, G., Wouters, M., Stevense-den Boer, M.A.M., Boers-Sonderen, M.J., Kapiteijn, E., Suijkerbuijk, K.P.M., Elias, S.G., Duin, I.A.J. van, Verheijden, R.J., Diest, P.J. van, Blokx, W.A.M., El-Sharouni, M.A., Verhoeff, J.J., Leiner, T., Eertwegh, A.J.M. van den, Groot, J.W.B. de, Not, O.J. van, Aarts, M.J.B., Berkmortel, F. van den, Blank, C.U., Haanen, J., Hospers, G.A.P., Piersma, D., Rijn, R.S. van, Veldt, A.A. van der, Vreugdenhil, G., Wouters, M., Stevense-den Boer, M.A.M., Boers-Sonderen, M.J., Kapiteijn, E., Suijkerbuijk, K.P.M., and Elias, S.G.
- Abstract
Contains fulltext : 305394.pdf (Publisher’s version ) (Open Access), Predicting who will benefit from treatment with immune checkpoint inhibition (ICI) in patients with advanced melanoma is challenging. We developed a multivariable prediction model for response to ICI, using routinely available clinical data including primary melanoma characteristics. We used a population-based cohort of 3525 patients with advanced cutaneous melanoma treated with anti-PD-1-based therapy. Our prediction model for predicting response within 6 months after ICI initiation was internally validated with bootstrap resampling. Performance evaluation included calibration, discrimination and internal-external cross-validation. Included patients received anti-PD-1 monotherapy (n = 2366) or ipilimumab plus nivolumab (n = 1159) in any treatment line. The model included serum lactate dehydrogenase, World Health Organization performance score, type and line of ICI, disease stage and time to first distant recurrence-all at start of ICI-, and location and type of primary melanoma, the presence of satellites and/or in-transit metastases at primary diagnosis and sex. The over-optimism adjusted area under the receiver operating characteristic was 0.66 (95% CI: 0.64-0.66). The range of predicted response probabilities was 7%-81%. Based on these probabilities, patients were categorized into quartiles. Compared to the lowest response quartile, patients in the highest quartile had a significantly longer median progression-free survival (20.0 vs 2.8 months; P < .001) and median overall survival (62.0 vs 8.0 months; P < .001). Our prediction model, based on routinely available clinical variables and primary melanoma characteristics, predicts response to ICI in patients with advanced melanoma and discriminates well between treated patients with a very good and very poor prognosis.
- Published
- 2024
10. Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
- Author
-
Mulder, E. E. A. P., de Joode, K., Litière, S., ten Tije, A. J., Suijkerbuijk, K. P. M., Boers-Sonderen, M. J., Hospers, G. A. P., de Groot, J. W. B., van den Eertwegh, A. J. M., Aarts, M. J. B., Piersma, D., van Rijn, R. S., Kapiteijn, E., Vreugdenhil, G., van den Berkmortel, F. W. P. J., Hoop, E. Oomen-de, Franken, M. G., Ryll, B., Rutkowski, P., Sleijfer, S., Haanen, J. B. A. G., and van der Veldt, A. A. M.
- Published
- 2021
- Full Text
- View/download PDF
11. Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort
- Author
-
Borgers, J. S. W., primary, Burgers, F. H., additional, Schina, A., additional, Van Not, O. J., additional, van den Eertwegh, A. J. M., additional, Blank, C. U., additional, Aarts, M. J. B., additional, van den Berkmortel, F. W. P. J., additional, de Groot, J. W. B., additional, Hospers, G. A. P., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R. S., additional, Boer, A. M. Stevense‐den, additional, van der Veldt, A. A. M., additional, Vreugdenhil, G., additional, Boers‐Sonderen, M. J., additional, Wouters, M. W. J. M., additional, Suijkerbuijk, K. P. M., additional, van Thienen, J. V., additional, and Haanen, J. B. A. G., additional
- Published
- 2023
- Full Text
- View/download PDF
12. The MMSE should not be the sole indicator of fitness to drive in mild Alzheimer’s dementia
- Author
-
Piersma, D., Fuermaier, A. B. M., de Waard, D., De Deyn, P. P., Davidse, R. J., de Groot, J., Doumen, M. J. A., Bredewoud, R. A., Claesen, R., Lemstra, A. W., Vermeeren, A., Ponds, R., Verhey, F., Brouwer, W. H., and Tucha, O.
- Published
- 2018
- Full Text
- View/download PDF
13. Adjuvant treatment with anti-PD-1 in acral melanoma: a nationwide study
- Author
-
Bloem, Manja, van Not, Olivier, Aarts, Maureen, van den Berkmortel FWPJ, Franchette, Blank CU, Christian, Blokx WAM, Willeke, Boers-Sonderen, Marije, Bonenkamp HJ, Han, Willem de Groot JWB, Jan, Haanen JBAG, John, Hospers GAP, Geke, Kapiteijn E, Ellen, Piersma D, Djura, van Rijn RS, Rozemarijn, Boer, Marion Stevense-de, van der Veldt A, Astrid, Art A, Vreugdenhil, van den Eertwegh AJM, Fons, Suijkerbuijk KPM, Karijn, and Wouters MWJM, Michel
- Published
- 2024
- Full Text
- View/download PDF
14. Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort.
- Author
-
Borgers, J. S. W., Burgers, F. H., Schina, A., Van Not, O. J., van den Eertwegh, A. J. M., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Boer, A. M. Stevense‐den, van der Veldt, A. A. M., Vreugdenhil, G., Boers‐Sonderen, M. J., Wouters, M. W. J. M., Suijkerbuijk, K. P. M., and van Thienen, J. V.
- Subjects
MELANOMA ,SEASONS ,OVERALL survival ,COUNTRIES ,SURVIVAL rate ,ENVIRONMENTAL exposure ,SEASONAL variations of diseases - Abstract
Despite the improved survival rates of patients with advanced stage melanoma since the introduction of ICIs, many patients do not have (long‐term) benefit from these treatments. There is evidence that the exposome, an accumulation of host‐extrinsic factors including environmental influences, could impact ICI response. Recently, a survival benefit was observed in patients with BRAF wild‐type melanoma living in Denmark who initiated immunotherapy in summer as compared to winter. As the Netherlands lies in close geographical proximity to Denmark and has comparable seasonal differences, a Dutch validation cohort was established using data from our nationwide melanoma registry. In this study, we did not observe a similar seasonal difference in overall survival and are therefore unable to confirm the Danish findings. Validation of either the Dutch or Danish findings in (combined) patient cohorts from other countries would be necessary to determine whether this host‐extrinsic factor influences the response to ICI‐treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
- Author
-
Blankenstein, S.A., Bonenkamp, J.J., Aarts, M.J., Berkmortel, F.W.P.J. van den, Blank, C.U., Blokx, W.A.M., Boers-Sonderen, M.J., Eertwegh, A.J. van den, Franken, M.G., Groot, J.W.B. de, Haanen, J.B.A.G., Hospers, G.A., Kapiteijn, E.W., Not, O.J. van, Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Veldt, A.A.M. van der, Vreugdenhil, G., Westgeest, H.M., Wouters, M.W., Akkooi, A.C. van, Blankenstein, S.A., Bonenkamp, J.J., Aarts, M.J., Berkmortel, F.W.P.J. van den, Blank, C.U., Blokx, W.A.M., Boers-Sonderen, M.J., Eertwegh, A.J. van den, Franken, M.G., Groot, J.W.B. de, Haanen, J.B.A.G., Hospers, G.A., Kapiteijn, E.W., Not, O.J. van, Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Veldt, A.A.M. van der, Vreugdenhil, G., Westgeest, H.M., Wouters, M.W., and Akkooi, A.C. van
- Abstract
01 januari 2023, Item does not contain fulltext
- Published
- 2023
16. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.
- Author
-
Kooij, M.K. van der, Joosse, A., Suijkerbuijk, K.P., Aarts, M.J., Berkmortel, F.W.P.J. van den, Blank, C.U., Boers-Sonderen, M.J., Eertwegh, A.J. van den, Groot, J.W.B. de, Haanen, J.B.A.G., Hospers, G.A., Piersma, D., Rijn, R.S. van, Veldt, A.A.M. van der, Vreugdenhil, G., Westgeest, H.M., Wouters, M.W., Dekkers, O.M., Kapiteijn, E., Kooij, M.K. van der, Joosse, A., Suijkerbuijk, K.P., Aarts, M.J., Berkmortel, F.W.P.J. van den, Blank, C.U., Boers-Sonderen, M.J., Eertwegh, A.J. van den, Groot, J.W.B. de, Haanen, J.B.A.G., Hospers, G.A., Piersma, D., Rijn, R.S. van, Veldt, A.A.M. van der, Vreugdenhil, G., Westgeest, H.M., Wouters, M.W., Dekkers, O.M., and Kapiteijn, E.
- Abstract
Item does not contain fulltext
- Published
- 2023
17. Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry.
- Author
-
Breeschoten, J. van, Eertwegh, A.J. van den, Hilarius, D.L., Haanen, J.B.A.G., Blank, C.U., Aarts, M.J., Berkmortel, F.W.P.J. van den, Groot, J.W.B. de, Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Stevense-den Boer, M.A.M., Veldt, A.A.M. van der, Vreugdenhil, G., Boers-Sonderen, M.J., Manevski, D., Suijkerbuijk, K.P., Wouters, M.W., Wreede, L.C. de, Breeschoten, J. van, Eertwegh, A.J. van den, Hilarius, D.L., Haanen, J.B.A.G., Blank, C.U., Aarts, M.J., Berkmortel, F.W.P.J. van den, Groot, J.W.B. de, Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Stevense-den Boer, M.A.M., Veldt, A.A.M. van der, Vreugdenhil, G., Boers-Sonderen, M.J., Manevski, D., Suijkerbuijk, K.P., Wouters, M.W., and Wreede, L.C. de
- Abstract
Item does not contain fulltext, INTRODUCTION: When analysing patient survival, one is often interested in cause of death. Little is known about the presence of population mortality in advanced melanoma patients. The aim of this study was to assess population mortality after different response states in advanced melanoma patients in the Netherlands, and analyse the contribution of disease and population mortality for different age groups. METHODS: We selected patients diagnosed between 2013 and 2019 with unresectable IIIC or stage IV melanoma, registered in the Dutch Melanoma Treatment Registry. A multi-state model with response states integrating population mortality was fitted. One-year landmark analyses were performed to assess outcomes after each response state. RESULTS: Overall, 5119 patients were selected. Five-year probabilities of melanoma-related mortality in patients alive in complete response at one year after diagnosis increased with age, and was 17.2% (95% confidence interval: 13.0-21.4) for patients aged <65 years and 28.7% (95% confidence interval: 24.3-33.1) in patients aged ≥80 years. Population mortality only played a large role for older patients (75 years and above) alive at 1 year after diagnosis with a partial or complete response. CONCLUSION: Even though survival outcomes of advanced melanoma patients have improved over the last decade, the vast majority of patients still die due to melanoma-related mortality.
- Published
- 2023
18. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
- Author
-
Blankenstein, S.A., Bonenkamp, J.J., Aarts, M.J., Berkmortel, F. van den, Blank, C.U., Blokx, W.A.M., Boers-Sonderen, M.J., Eertwegh, A.J. van den, Franken, M.G., Groot, J.W.B. de, Haanen, J., Hospers, G.A., Kapiteijn, E.W., Not, O.J. van, Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Veldt, A.A.M. van der, Vreugdenhil, G., Westgeest, H.M., Wouters, M., Akkooi, A.C. van, Blankenstein, S.A., Bonenkamp, J.J., Aarts, M.J., Berkmortel, F. van den, Blank, C.U., Blokx, W.A.M., Boers-Sonderen, M.J., Eertwegh, A.J. van den, Franken, M.G., Groot, J.W.B. de, Haanen, J., Hospers, G.A., Kapiteijn, E.W., Not, O.J. van, Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Veldt, A.A.M. van der, Vreugdenhil, G., Westgeest, H.M., Wouters, M., and Akkooi, A.C. van
- Abstract
Item does not contain fulltext, INTRODUCTION: Sentinel lymph node biopsy (SLNB) is important for staging in patients with primary cutaneous melanoma. Did having previously undergone SLNB also affect outcomes in patients once they have progressed to metastatic melanoma in the era prior to adjuvant therapy? METHODS: Data were retrieved from the Dutch Melanoma Treatment Registry, a prospectively collected, nationwide database of patients with unresectable stage IIIC or IV (advanced) melanoma between 2012 and 2018. Melanoma-specific survival (MSS) was compared between patients with advanced cutaneous melanoma, previously treated with a wide local excision (WLE) or WLE combined with SLNB as initial treatment of their primary tumor. Cox regression analyses were used to analyze the influence of different variables on MSS. RESULTS: In total, 2581 patients were included, of whom 1412 were treated with a WLE of the primary tumor alone and 1169 in whom this was combined with SLNB. At a median follow-up of 44 months from diagnosis of advanced melanoma, MSS was significantly longer in patients who had previously undergone SLNB {median 23 months (95% confidence interval [CI] 19-29) vs. 18 months (95% CI 15-20) for patients treated with WLE alone; p = 0.002}. However, multivariate Cox regression did not identify SLNB as an independent favorable prognostic factor for MSS after diagnosis of advanced melanoma. CONCLUSION: Prior to the availability of adjuvant systemic therapy, once patients have unresectable stage IIIC or IV (advanced) melanoma, there was no difference in disease outcome for patients who were or were not previously staged with SLNB.
- Published
- 2023
19. Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands.
- Author
-
Zeijl, M.C.T. van, Breeschoten, J. van, Wreede, L.C. de, Wouters, M.W., Hilarius, D.L., Blank, C.U., Aarts, M.J., Berkmortel, F.W.P.J. van den, Groot, J.W.B. de, Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Stevense-den Boer, M., Veldt, A.A.M. van der, Vreugdenhil, G., Boers-Sonderen, M.J., Suijkerbuijk, K.P., Haanen, J.B.A.G., Eertwegh, A.J. van den, Zeijl, M.C.T. van, Breeschoten, J. van, Wreede, L.C. de, Wouters, M.W., Hilarius, D.L., Blank, C.U., Aarts, M.J., Berkmortel, F.W.P.J. van den, Groot, J.W.B. de, Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Stevense-den Boer, M., Veldt, A.A.M. van der, Vreugdenhil, G., Boers-Sonderen, M.J., Suijkerbuijk, K.P., Haanen, J.B.A.G., and Eertwegh, A.J. van den
- Abstract
Item does not contain fulltext, In phase III trials, ipilimumab plus nivolumab combination therapy is highly efficacious for advanced melanoma, despite many treatment-related grades 3-4 adverse events. Here, we report real-world safety and survival outcomes of ipilimumab plus nivolumab for advanced melanoma. Patients with advanced melanoma who received first-line ipilimumab plus nivolumab between January 1, 2015 and June 30, 2021 were selected from the Dutch Melanoma Treatment Registry. We evaluated response status at 3, 6, 12, 18, and 24 months. OS and PFS were estimated with the Kaplan-Meier method. Separate analyses were performed for patients with or without brain metastases and for patients who met the inclusion criteria of the Checkmate-067 trial. In total, 709 patients received first-line ipilimumab plus nivolumab. Three hundred sixty (50.7%) patients experienced grade 3-4 adverse events, with 211 of the (58.6%) patients requiring hospital admission. The median treatment duration was 42 days (IQR = 31-139). At 24 months, disease control was achieved in 37% of patients. Median PFS since the start of treatment was 6.6 months (95% CI: 5.3-8.7), and median OS was 28.7 months (95% CI: 20.7-42.2). CheckMate-067 trial-like patients had a 4-year OS of 50% (95% CI: 43-59). Among patients with no asymptomatic or symptomatic brain metastases, the 4-year OS probabilities were 48% (95% CI: 41-55), 45% (95% CI: 35-57), and 32% (95% CI: 23-46). Ipilimumab plus nivolumab can achieve long-term survival in advanced melanoma patients in a real-world setting, including patients not represented in the CheckMate-067 trial. However, the proportion of patients with disease control in the real world is lower compared with clinical trials.
- Published
- 2023
20. Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials.
- Author
-
Meza, M.M. De, Blokx, W.A.M., Bonenkamp, H., Blank, C.U., Aarts, M.J., Berkmortel, F.W.P.J. van den, Boers-Sonderen, M.J., Groot, J.W.B. de, Haanen, J.B.A.G., Hospers, G.A., Kapiteijn, E.W., Not, O.J. van, Piersma, D., Rijn, R.S. van, vense-Den Boer, M.A. Ste, Veldt, A.A.M. van der, Vreugdenhil, G., Eertwegh, A.J. van den, Suijkerbuijk, K.P., Wouters, M.W., Meza, M.M. De, Blokx, W.A.M., Bonenkamp, H., Blank, C.U., Aarts, M.J., Berkmortel, F.W.P.J. van den, Boers-Sonderen, M.J., Groot, J.W.B. de, Haanen, J.B.A.G., Hospers, G.A., Kapiteijn, E.W., Not, O.J. van, Piersma, D., Rijn, R.S. van, vense-Den Boer, M.A. Ste, Veldt, A.A.M. van der, Vreugdenhil, G., Eertwegh, A.J. van den, Suijkerbuijk, K.P., and Wouters, M.W.
- Abstract
Item does not contain fulltext, Few clinical trials address efficacy of adjuvant systemic treatment in patients with in-transit melanoma (ITM). This study describes adjuvant systemic therapy of ITM patients beyond clinical trials. In this study, we included stage III adjuvant-treated melanoma patients registered in the nationwide Dutch Melanoma Treatment Registry between July 2018 and December 2020. Patients were divided into three groups: nodal disease only, ITM only and ITM and nodal disease. Recurrence patterns, recurrence-free survival (RFS) and overall survival (OS) at 12-months were analyzed. In our study population of 1037 patients, 66.8% had nodal disease only, 16.7% had ITM only and 16.2% had ITM with nodal disease. RFS at 12-months was comparable in the nodal only and ITM only group (72.2% vs70.1%, P = .97) but lower in ITM and nodal disease patients (57.8%; P = .01, P < .01). Locoregional metastases occurred as first recurrence in 38.9% nodal disease only, 71.9% of ITM-only and 44.0% of ITM and nodal disease patients. Distant recurrences occurred in 42.3%, 18.8% and 36.0%, respectively (P = .02). 12-months OS was not significantly different for nodal disease only patients compared with ITM-only (94.4% vs 97.6%, P = .06) but was significantly higher for ITM-only compared with ITM and nodal disease patients (97.6% vs 91.0%, P < .01). In conclusion, we showed that in the adjuvant setting, RFS rates in ITM-only patients are similar to non-ITM, though better than in ITM and nodal disease patients. Adjuvant-treated ITM-only patients less often experience distant recurrences and have a superior OS compared with ITM and nodal disease patients.
- Published
- 2023
21. A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.
- Author
-
Not, O.J. van, Wind, T.T., Ismail, R.K., Bhattacharya, A., Jalving, M., Blank, C.U., Aarts, M.J., Berkmortel, F.W.P.J. van den, Boers-Sonderen, M.J., Eertwegh, A.J. van den, Groot, J.W.B. de, Haanen, J.B.A.G., Kapiteijn, E., Bloem, M., Piersma, D., Rijn, R.S. van, vense-den Boer, M. Ste, Veldt, A.A.M. van der, Vreugdenhil, G., Wouters, M.W., Blokx, W.A.M., Suijkerbuijk, K.P., Fehrmann, R.S., Hospers, G.A., Not, O.J. van, Wind, T.T., Ismail, R.K., Bhattacharya, A., Jalving, M., Blank, C.U., Aarts, M.J., Berkmortel, F.W.P.J. van den, Boers-Sonderen, M.J., Eertwegh, A.J. van den, Groot, J.W.B. de, Haanen, J.B.A.G., Kapiteijn, E., Bloem, M., Piersma, D., Rijn, R.S. van, vense-den Boer, M. Ste, Veldt, A.A.M. van der, Vreugdenhil, G., Wouters, M.W., Blokx, W.A.M., Suijkerbuijk, K.P., Fehrmann, R.S., and Hospers, G.A.
- Abstract
Item does not contain fulltext, The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma that develop brain metastases (BM) remains unpredictable. In this study, we aimed to identify prognostic factors in patients with melanoma BM who are treated with ICIs. Data from advanced melanoma patients with BM treated with ICIs in any line between 2013 and 2020 were obtained from the Dutch Melanoma Treatment Registry. Patients were included from the time of the treatment of BM with ICIs. Survival tree analysis was performed with clinicopathological parameters as potential classifiers and overall survival (OS) as the response variable. In total, 1278 patients were included. Most patients were treated with ipilimumab-nivolumab combination therapy (45%). The survival tree analysis resulted in 31 subgroups. The median OS ranged from 2.7 months to 35.7 months. The strongest clinical parameter associated with survival in advanced melanoma patients with BM was the serum lactate dehydrogenase (LDH) level. Patients with elevated LDH levels and symptomatic BM had the worst prognosis. The clinicopathological classifiers identified in this study can contribute to optimizing clinical studies and can aid doctors in giving an indication of the patients' survival based on their baseline and disease characteristics.
- Published
- 2023
22. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma
- Author
-
Maat, L.S. Ter, Duin, I.A.J. van, Elias, S.G., Leiner, T., Verhoeff, J.J., Arntz, E., Troenokarso, M.F., Blokx, W.A.M., Isgum, I., Wit, G.A. de, Berkmortel, F. van den, Boers-Sonderen, M.J., Boomsma, M.F., Eertwegh, F.J.M. van den, Groot, J.W.B. de, Piersma, D., Vreugdenhil, A., Westgeest, H.M., Kapiteijn, E., Diest, P.J. van, Pluim, J.P., Jong, P.A. de, Suijkerbuijk, K.P., Veta, M., Maat, L.S. Ter, Duin, I.A.J. van, Elias, S.G., Leiner, T., Verhoeff, J.J., Arntz, E., Troenokarso, M.F., Blokx, W.A.M., Isgum, I., Wit, G.A. de, Berkmortel, F. van den, Boers-Sonderen, M.J., Boomsma, M.F., Eertwegh, F.J.M. van den, Groot, J.W.B. de, Piersma, D., Vreugdenhil, A., Westgeest, H.M., Kapiteijn, E., Diest, P.J. van, Pluim, J.P., Jong, P.A. de, Suijkerbuijk, K.P., and Veta, M.
- Abstract
Item does not contain fulltext, INTRODUCTION: Predicting checkpoint inhibitors treatment outcomes in melanoma is a relevant task, due to the unpredictable and potentially fatal toxicity and high costs for society. However, accurate biomarkers for treatment outcomes are lacking. Radiomics are a technique to quantitatively capture tumour characteristics on readily available computed tomography (CT) imaging. The purpose of this study was to investigate the added value of radiomics for predicting clinical benefit from checkpoint inhibitors in melanoma in a large, multicenter cohort. METHODS: Patients who received first-line anti-PD1±anti-CTLA4 treatment for advanced cutaneous melanoma were retrospectively identified from nine participating hospitals. For every patient, up to five representative lesions were segmented on baseline CT, and radiomics features were extracted. A machine learning pipeline was trained on the radiomics features to predict clinical benefit, defined as stable disease for more than 6 months or response per RECIST 1.1 criteria. This approach was evaluated using a leave-one-centre-out cross validation and compared to a model based on previously discovered clinical predictors. Lastly, a combination model was built on the radiomics and clinical model. RESULTS: A total of 620 patients were included, of which 59.2% experienced clinical benefit. The radiomics model achieved an area under the receiver operator characteristic curve (AUROC) of 0.607 [95% CI, 0.562-0.652], lower than that of the clinical model (AUROC=0.646 [95% CI, 0.600-0.692]). The combination model yielded no improvement over the clinical model in terms of discrimination (AUROC=0.636 [95% CI, 0.592-0.680]) or calibration. The output of the radiomics model was significantly correlated with three out of five input variables of the clinical model (p < 0.001). DISCUSSION: The radiomics model achieved a moderate predictive value of clinical benefit, which was statistically significant. However, a radiomics approach was unable
- Published
- 2023
23. Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
- Author
-
Duin, I.A.J. van, Elias, S.G., Eertwegh, A.J.M. van den, Groot, J.W.B. de, Blokx, W.A.M., Diest, P.J. van, Leiner, T., Verhoeff, J.J.C., Verheijden, R.J., Not, O.J. van, Aarts, M.J.B., Berkmortel, F. van den, Blank, C.U., Haanen, J., Hospers, G.A.P., Kamphuis, A.M., Piersma, D., Rijn, R.S. van, Veldt, A.A.M. van der, Vreugdenhil, G., Wouters, M., Stevense-den Boer, M.A.M., Boers-Sonderen, M.J., Kapiteijn, E., Suijkerbuijk, K.P.M., Duin, I.A.J. van, Elias, S.G., Eertwegh, A.J.M. van den, Groot, J.W.B. de, Blokx, W.A.M., Diest, P.J. van, Leiner, T., Verhoeff, J.J.C., Verheijden, R.J., Not, O.J. van, Aarts, M.J.B., Berkmortel, F. van den, Blank, C.U., Haanen, J., Hospers, G.A.P., Kamphuis, A.M., Piersma, D., Rijn, R.S. van, Veldt, A.A.M. van der, Vreugdenhil, G., Wouters, M., Stevense-den Boer, M.A.M., Boers-Sonderen, M.J., Kapiteijn, E., and Suijkerbuijk, K.P.M.
- Abstract
Item does not contain fulltext, Since the introduction of BRAF(/MEK) inhibition and immune checkpoint inhibition (ICI), the prognosis of advanced melanoma has greatly improved. Melanoma is known for its remarkably long time to first distant recurrence (TFDR), which can be decades in some patients and is partly attributed to immune-surveillance. We investigated the relationship between TFDR and patient outcomes after systemic treatment for advanced melanoma. We selected patients undergoing first-line systemic therapy for advanced melanoma from the nationwide Dutch Melanoma Treatment Registry. The association between TFDR and progression-free survival (PFS) and overall survival (OS) was assessed by Cox proportional hazard regression models. The TFDR was modeled categorically, linearly, and flexibly using restricted cubic splines. Patients received anti-PD-1-based treatment (n = 1844) or BRAF(/MEK) inhibition (n = 1618). For ICI-treated patients with a TFDR <2 years, median OS was 25.0 months, compared to 37.3 months for a TFDR >5 years (P = .014). Patients treated with BRAF(/MEK) inhibition with a longer TFDR also had a significantly longer median OS (8.6 months for TFDR <2 years compared to 11.1 months for >5 years, P = .004). The hazard of dying rapidly decreased with increasing TFDR until approximately 5 years (HR 0.87), after which the hazard of dying further decreased with increasing TFDR, but less strongly (HR 0.82 for a TFDR of 10 years and HR 0.79 for a TFDR of 15 years). Results were similar when stratifying for type of treatment. Advanced melanoma patients with longer TFDR have a prolonged PFS and OS, irrespective of being treated with first-line ICI or targeted therapy.
- Published
- 2023
24. Health-state utilities in long-term advanced melanoma survivors comparable with the general population
- Author
-
MS Medische Oncologie, Cancer, Infection & Immunity, Egeler, M D, van de Poll-Franse, L V, Tissier, R, Rogiers, A, Boers-Sonderen, M J, van den Eertwegh, A J, Hospers, G A, de Groot, J W B, Aarts, M J B, Kapiteijn, E, Piersma, D, Vreugdenhil, G, van der Veldt, A A, Suijkerbuijk, K P M, Neyns, B, Janssen, K J, Blank, C U, Retèl, V P, Boekhout, A H, MS Medische Oncologie, Cancer, Infection & Immunity, Egeler, M D, van de Poll-Franse, L V, Tissier, R, Rogiers, A, Boers-Sonderen, M J, van den Eertwegh, A J, Hospers, G A, de Groot, J W B, Aarts, M J B, Kapiteijn, E, Piersma, D, Vreugdenhil, G, van der Veldt, A A, Suijkerbuijk, K P M, Neyns, B, Janssen, K J, Blank, C U, Retèl, V P, and Boekhout, A H
- Published
- 2023
25. CT radiomics to predict checkpoint inhibitors treatment outcomes in patients with advanced cutaneous melanoma
- Author
-
ter Maat, L.S., primary, van Duin, I.A.J., additional, Elias, S.G., additional, Leiner, T., additional, Verhoeff, J.J.C., additional, Arntz, E.R.A.N., additional, Troenokarso, M.F., additional, Blokx, W.A.M., additional, Isgum, I., additional, de Wit, G.A., additional, van den Berkmortel, F.W.P.J., additional, Boers-Sonderen, M.J., additional, Boomsma, M.F., additional, van den Eertwegh, A.J.M., additional, de Groot, J.W.B., additional, Piersma, D., additional, Vreugdenhil, G., additional, Westgeest, H.M, additional, Kapiteijn, E., additional, van Diest, P.J., additional, Pluim, J.P.W., additional, de Jong, P.A., additional, Suijkerbuijk, K.P.M., additional, and Veta, M., additional
- Published
- 2022
- Full Text
- View/download PDF
26. 849P Time from primary melanoma to first distant recurrence in relation to survival outcomes in metastatic melanoma
- Author
-
van Duin, I.A.J., primary, Elias, S.G., additional, Van Den Eertwegh, F., additional, de Groot, J.W.B., additional, Blokx, W.A.M., additional, van Not, O.J., additional, Aarts, M., additional, Blank, C.U., additional, Haanen, J.B.A.G., additional, Hospers, G., additional, Piersma, D., additional, van Rijn, R.S., additional, Stevense-den Boer, M., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Wouters, M., additional, Van den Berkmortel, F., additional, Boers-Sonderen, M., additional, Kapiteijn, E., additional, and Suijkerbuijk, K.P.M., additional
- Published
- 2022
- Full Text
- View/download PDF
27. 859P The influence of hematologic malignancies on response to immune checkpoint inhibition in patients with advanced melanoma
- Author
-
van Not, O.J., primary, Van Den Eertwegh, F., additional, Haanen, J.B.A.G., additional, van Rijn, R.S., additional, Aarts, M., additional, Van den Berkmortel, F., additional, Blank, C.U., additional, Boers-Sonderen, M., additional, de Groot, J.W.B., additional, Hospers, G., additional, Kapiteijn, E., additional, De Meza, M.M., additional, Piersma, D., additional, Stevense-den Boer, M., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Wouters, M., additional, Blokx, W.A.M., additional, and Suijkerbuijk, K.P.M., additional
- Published
- 2022
- Full Text
- View/download PDF
28. 1140TiP Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
- Author
-
Janssen, J.C., van Dijk, B., de Joode, K., Aarts, M., Van den Berkmortel, F., Blank, C.U., Boers-Sonderen, M., Van Den Eertwegh, F., de Groot, J.W., Jalving, M., Joosse, A., Huismans, A., Kapiteijn, E., Naipal, K.A.T., Piersma, D., Rikhof, B., Vreugdenhil, G., Westgeest, H.M., Mulder, E.E.A.P., and Van der Veldt, A.A.M.
- Published
- 2024
- Full Text
- View/download PDF
29. Survival of stage IV melanoma in Belgium and the Netherlands
- Author
-
Suijkerbuijk, K.P., Haanen, J., Boers-Sonderen, M.J., Hospers, G.A., Blank, C.U., Berkmortel, F. van den, Groot, J.W.B. de, Piersma, D., Aarts, M.J., Rijn, R.S. van, Vreugdenhil, G., Westgeest, H.M., Kapiteijn, E., Veldt, A.A.M. van der, Eertwegh, A.J. van den, Suijkerbuijk, K.P., Haanen, J., Boers-Sonderen, M.J., Hospers, G.A., Blank, C.U., Berkmortel, F. van den, Groot, J.W.B. de, Piersma, D., Aarts, M.J., Rijn, R.S. van, Vreugdenhil, G., Westgeest, H.M., Kapiteijn, E., Veldt, A.A.M. van der, and Eertwegh, A.J. van den
- Abstract
Item does not contain fulltext
- Published
- 2022
30. The unfavorable effects of COVID-19 on Dutch advanced melanoma care
- Author
-
Not, O.J. van, Breeschoten, J. van, Eertwegh, A.J. van den, Hilarius, D.L., Meza, M.M. De, Haanen, J.B.A.G., Blank, C.U., Aarts, M.J., Berkmortel, F. van den, Groot, J.W.B. de, Hospers, G.A., Ismail, R.K., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Stevense-den Boer, M.A.M., Veldt, A.A.M. van der, Vreugdenhil, G., Boers-Sonderen, M.J., Blokx, W.A.M., Suijkerbuijk, K.P., Wouters, M., Not, O.J. van, Breeschoten, J. van, Eertwegh, A.J. van den, Hilarius, D.L., Meza, M.M. De, Haanen, J.B.A.G., Blank, C.U., Aarts, M.J., Berkmortel, F. van den, Groot, J.W.B. de, Hospers, G.A., Ismail, R.K., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Stevense-den Boer, M.A.M., Veldt, A.A.M. van der, Vreugdenhil, G., Boers-Sonderen, M.J., Blokx, W.A.M., Suijkerbuijk, K.P., and Wouters, M.
- Abstract
Contains fulltext : 244556.pdf (Publisher’s version ) (Open Access), The COVID-19 pandemic had a severe impact on medical care. Our study aims to investigate the impact of COVID-19 on advanced melanoma care in the Netherlands. We selected patients diagnosed with irresectable stage IIIc and IV melanoma during the first and second COVID-19 wave and compared them with patients diagnosed within the same time frame in 2018 and 2019. Patients were divided into three geographical regions. We investigated baseline characteristics, time from diagnosis until start of systemic therapy and postponement of anti-PD-1 courses. During both waves, fewer patients were diagnosed compared to the control groups. During the first wave, time between diagnosis and start of treatment was significantly longer in the southern region compared to other regions (33 vs 9 and 15 days, P-value <.05). Anti-PD-1 courses were postponed in 20.0% vs 3.0% of patients in the first wave compared to the control period. Significantly more patients had courses postponed in the south during the first wave compared to other regions (34.8% vs 11.5% vs 22.3%, P-value <.001). Significantly more patients diagnosed during the second wave had brain metastases and worse performance status compared to the control period. In conclusion, advanced melanoma care in the Netherlands was severely affected by the COVID-19 pandemic. In the south, the start of systemic treatment for advanced melanoma was more often delayed, and treatment courses were more frequently postponed. During the second wave, patients were diagnosed with poorer patient and tumor characteristics. Longer follow-up is needed to establish the impact on patient outcomes.
- Published
- 2022
31. Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice
- Author
-
Zeijl, M.C.T. van, Eertwegh, A.J. van den, Wouters, M., Wreede, L.C. de, Aarts, M.J., Berkmortel, F. van den, Groot, J.B. de, Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Tije, A.J. Ten, Veldt, A.A.M. van der, Vreugdenhil, G., Hoeven, J.J.M. van der, Haanen, J., Zeijl, M.C.T. van, Eertwegh, A.J. van den, Wouters, M., Wreede, L.C. de, Aarts, M.J., Berkmortel, F. van den, Groot, J.B. de, Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Tije, A.J. Ten, Veldt, A.A.M. van der, Vreugdenhil, G., Hoeven, J.J.M. van der, and Haanen, J.
- Abstract
Item does not contain fulltext, There is no consensus on the optimal treatment duration of anti-PD-1 for advanced melanoma. The aim of our study was to gain insight into the outcomes of anti-PD-1 discontinuation, the association of treatment duration with progression and anti-PD-1 re-treatment in relapsing patients. Analyses were performed on advanced melanoma patients in the Netherlands who discontinued first-line anti-PD-1 monotherapy in the absence of progressive disease (n = 324). Survival was estimated after anti-PD-1 discontinuation and with a Cox model the association of treatment duration with progression was assessed. At the time of anti-PD-1 discontinuation, 90 (28%) patients had a complete response (CR), 190 (59%) a partial response (PR) and 44 (14%) stable disease (SD). Median treatment duration for patients with CR, PR and SD was 11.2, 11.5 and 7.2 months, respectively. The 24-month progression-free survival and overall survival probabilities for patients with a CR, PR and SD were, respectively, 64% and 88%, 53% and 82%, 31% and 64%. Survival outcomes of patients with a PR and CR were similar when anti-PD-1 discontinuation was not due to adverse events. Having a PR at anti-PD-1 discontinuation and longer time to first response were associated with progression [hazard ratio (HR) = 1.81 (95% confidence interval, CI = 1.11-2.97) and HR = 1.10 (95% CI = 1.02-1.19; per month increase)]. In 17 of the 27 anti-PD-1 re-treated patients (63%), a response was observed. Advanced melanoma patients can have durable remissions after (elective) anti-PD-1 discontinuation.
- Published
- 2022
32. BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma
- Author
-
Not, O.J. van, Blokx, W.A.M., Eertwegh, A.J. van den, Meza, M.M. De, Haanen, J.B.A.G., Blank, C.U., Aarts, M.J., Berkmortel, F. van den, Groot, J.W.B. de, Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Stevense-den Boer, M., Veldt, A.A.M. van der, Boers-Sonderen, M.J., Jansen, A.M.L., Wouters, M., Suijkerbuijk, K.P., Not, O.J. van, Blokx, W.A.M., Eertwegh, A.J. van den, Meza, M.M. De, Haanen, J.B.A.G., Blank, C.U., Aarts, M.J., Berkmortel, F. van den, Groot, J.W.B. de, Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Stevense-den Boer, M., Veldt, A.A.M. van der, Boers-Sonderen, M.J., Jansen, A.M.L., Wouters, M., and Suijkerbuijk, K.P.
- Abstract
Item does not contain fulltext, PURPOSE: Little is known about the effect of specific gene mutations on efficacy of immune checkpoint inhibitors in patients with advanced melanoma. MATERIALS AND METHODS: All patients with advanced melanoma treated with first-line anti-PD-1 or ipilimumab-nivolumab between 2012 and 2021 in the nationwide Dutch Melanoma Treatment Registry were included in this cohort study. Objective response rate, progression-free survival (PFS), and overall survival (OS) were analyzed according to BRAF and NRAS status. A multivariable Cox model was used to analyze prognostic factors associated with PFS and OS. RESULTS: In total, 1764 patients received anti-PD-1 and 759 received ipilimumab-nivolumab. No significant differences in PFS were found in the anti-PD-1 cohort. In the ipilimumab-nivolumab cohort, median PFS was significantly higher for BRAF-mutant melanoma (9.9 months; 95% CI, 6.8 to 17.2) compared with NRAS-mutant (4.8 months; 95% CI, 3.0 to 7.5) and double wild-type (5.3 months; 95% CI, 3.6 to 7.1). In multivariable analysis, BRAF-mutant melanoma was significantly associated with a lower risk of progression or death in the ipilimumab-nivolumab cohort. Median OS was significantly higher for BRAF-mutant melanoma compared with NRAS-mutant and double wild-type melanoma for both immune checkpoint inhibitor regimens. CONCLUSION: Ipilimumab-nivolumab-treated patients with BRAF-mutant melanoma display improved PFS and OS compared with patients with NRAS-mutant and double wild-type melanoma. BRAF mutation status is a factor to consider while choosing between mono and dual checkpoint inhibition in advanced melanoma.
- Published
- 2022
33. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
- Author
-
Rohaan, M.W., Borch, T.H., Berg, J.H. van den, Met, Ö., Kessels, R., Foppen, M.H. Geukes, Granhøj, J. Stoltenborg, Nuijen, B., Nijenhuis, C., Jedema, I., Zon, M. van, Scheij, S., Beijnen, J.H., Hansen, M., Voermans, C., Noringriis, I.M., Monberg, T.J., Holmstroem, R.B., Wever, L.D.V., Dijk, M van, Grijpink-Ongering, L.G., Valkenet, L.H.M., Acosta, A. Torres, Karger, M., Borgers, J.S.W., Ham, R.M.T. Ten, Retèl, V.P., Harten, W.H. van, Lalezari, F., Tinteren, H. van, Veldt, A.A.M. van der, Hospers, G.A., Stevense-den Boer, M.A.M., Suijkerbuijk, K.P., Aarts, M.J., Piersma, D., Eertwegh, A.J. van den, Groot, J.B. de, Vreugdenhil, G., Kapiteijn, E., Boers-Sonderen, M.J., Fiets, W.E., Berkmortel, F. van den, Ellebaek, E., Hölmich, L.R., Akkooi, A.C. van, Houdt, W.J. van, Wouters, M., Thienen, J.V. van, Blank, C.U., Meerveld-Eggink, A., Klobuch, S., Wilgenhof, S., Schumacher, T.N., Donia, M., Svane, I.M., Haanen, J., Rohaan, M.W., Borch, T.H., Berg, J.H. van den, Met, Ö., Kessels, R., Foppen, M.H. Geukes, Granhøj, J. Stoltenborg, Nuijen, B., Nijenhuis, C., Jedema, I., Zon, M. van, Scheij, S., Beijnen, J.H., Hansen, M., Voermans, C., Noringriis, I.M., Monberg, T.J., Holmstroem, R.B., Wever, L.D.V., Dijk, M van, Grijpink-Ongering, L.G., Valkenet, L.H.M., Acosta, A. Torres, Karger, M., Borgers, J.S.W., Ham, R.M.T. Ten, Retèl, V.P., Harten, W.H. van, Lalezari, F., Tinteren, H. van, Veldt, A.A.M. van der, Hospers, G.A., Stevense-den Boer, M.A.M., Suijkerbuijk, K.P., Aarts, M.J., Piersma, D., Eertwegh, A.J. van den, Groot, J.B. de, Vreugdenhil, G., Kapiteijn, E., Boers-Sonderen, M.J., Fiets, W.E., Berkmortel, F. van den, Ellebaek, E., Hölmich, L.R., Akkooi, A.C. van, Houdt, W.J. van, Wouters, M., Thienen, J.V. van, Blank, C.U., Meerveld-Eggink, A., Klobuch, S., Wilgenhof, S., Schumacher, T.N., Donia, M., Svane, I.M., and Haanen, J.
- Abstract
Item does not contain fulltext, BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) have shown promising responses, but data from phase 3 trials are lacking to determine the role of TILs in treating advanced melanoma. METHODS: In this phase 3, multicenter, open-label trial, we randomly assigned patients with unresectable stage IIIC or IV melanoma in a 1:1 ratio to receive TIL or anti-cytotoxic T-lymphocyte antigen 4 therapy (ipilimumab at 3 mg per kilogram of body weight). Infusion of at least 5×10(9) TILs was preceded by nonmyeloablative, lymphodepleting chemotherapy (cyclophosphamide plus fludarabine) and followed by high-dose interleukin-2. The primary end point was progression-free survival. RESULTS: A total of 168 patients (86% with disease refractory to anti-programmed death 1 treatment) were assigned to receive TILs (84 patients) or ipilimumab (84 patients). In the intention-to-treat population, median progression-free survival was 7.2 months (95% confidence interval [CI], 4.2 to 13.1) in the TIL group and 3.1 months (95% CI, 3.0 to 4.3) in the ipilimumab group (hazard ratio for progression or death, 0.50; 95% CI, 0.35 to 0.72; P<0.001); 49% (95% CI, 38 to 60) and 21% (95% CI, 13 to 32) of the patients, respectively, had an objective response. Median overall survival was 25.8 months (95% CI, 18.2 to not reached) in the TIL group and 18.9 months (95% CI, 13.8 to 32.6) in the ipilimumab group. Treatment-related adverse events of grade 3 or higher occurred in all patients who received TILs and in 57% of those who received ipilimumab; in the TIL group, these events were mainly chemotherapy-related myelosuppression. CONCLUSIONS: In patients with advanced melanoma, progression-free survival was significantly longer among those who received TIL therapy than amon
- Published
- 2022
34. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
- Author
-
Not, O.J. van, Verheijden, R.J., Eertwegh, A.J. van den, Haanen, J., Aarts, M.J., Berkmortel, F. van den, Blank, C.U., Boers-Sonderen, M.J., Groot, J.B. de, Hospers, G.A., Kamphuis, A.M., Kapiteijn, E., May, A.M., Meza, M.M. De, Piersma, D., Rijn, R van, Stevense-den Boer, M.A.M., Veldt, A.A.M. van der, Vreugdenhil, G., Blokx, W.A.M., Wouters, M.J.M., Suijkerbuijk, K.P., Not, O.J. van, Verheijden, R.J., Eertwegh, A.J. van den, Haanen, J., Aarts, M.J., Berkmortel, F. van den, Blank, C.U., Boers-Sonderen, M.J., Groot, J.B. de, Hospers, G.A., Kamphuis, A.M., Kapiteijn, E., May, A.M., Meza, M.M. De, Piersma, D., Rijn, R van, Stevense-den Boer, M.A.M., Veldt, A.A.M. van der, Vreugdenhil, G., Blokx, W.A.M., Wouters, M.J.M., and Suijkerbuijk, K.P.
- Abstract
Item does not contain fulltext, IMPORTANCE: Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects of anti-tumor necrosis factor on checkpoint-inhibitor efficacy. OBJECTIVE: To determine the association of toxic effect management with progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS) in patients with advanced melanoma treated with first-line ipilimumab-nivolumab combination therapy. DESIGN, SETTING, AND PARTICIPANTS: This population-based, multicenter cohort study included patients with advanced melanoma experiencing grade 3 and higher irAEs after treatment with first-line ipilimumab and nivolumab between 2015 and 2021. Data were collected from the Dutch Melanoma Treatment Registry. Median follow-up was 23.6 months. MAIN OUTCOMES AND MEASURES: The PFS, OS, and MSS were analyzed according to toxic effect management regimen. Cox proportional hazard regression was used to assess factors associated with PFS and OS. RESULTS: Of 771 patients treated with ipilimumab and nivolumab, 350 patients (median [IQR] age, 60.0 [51.0-68.0] years; 206 [58.9%] male) were treated with immunosuppression for severe irAEs. Of these patients, 235 received steroids alone, and 115 received steroids with second-line immunosuppressants. Colitis and hepatitis were the most frequently reported types of toxic effects. Except for type of toxic effect, no statistically significant differences existed at baseline. Median PFS was statistically significantly longer for patients treated with steroids alone compared with patients treated with steroids plus second-line immunosuppressants (11.3 [95% CI, 9.6-19.6] months vs 5.4 [95% CI, 4.5-12.4] months; P = .01). Median OS was also statistically significantly longer for the group receiving steroids alone compared with those receiving steroids plus second-line immunosuppressants (46.1 months [95% CI, 39.0 months-not reached (NR)] vs 2
- Published
- 2022
35. Survival of stage IV melanoma in Belgium and the Netherlands
- Author
-
MS Medische Oncologie, Infection & Immunity, Cancer, Anatomie, MS MOD, MS KNO, Suijkerbuijk, K. P.M., Haanen, J. B.A.G., Boers-Sonderen, M. J., Hospers, G. A.P., Blank, C. U., van den Berkmortel, F. W.P.J., de Groot, J. W.B., Piersma, D., Aarts, M. J.B., van Rijn, R. S., Vreugdenhil, G., Westgeest, H. M., Kapiteijn, E., van der Veldt, A. A.M., van den Eertwegh, A. J.M., MS Medische Oncologie, Infection & Immunity, Cancer, Anatomie, MS MOD, MS KNO, Suijkerbuijk, K. P.M., Haanen, J. B.A.G., Boers-Sonderen, M. J., Hospers, G. A.P., Blank, C. U., van den Berkmortel, F. W.P.J., de Groot, J. W.B., Piersma, D., Aarts, M. J.B., van Rijn, R. S., Vreugdenhil, G., Westgeest, H. M., Kapiteijn, E., van der Veldt, A. A.M., and van den Eertwegh, A. J.M.
- Published
- 2022
36. The development of a flexible and easy to tailor disease model to estimate the outcomes of treatment sequences in advanced melanoma by combining trial and real-world data
- Author
-
de Groot, S., Blommestein, H. M., Leeneman, B., Uyl-De Groot, C. A., Haanen, J. B. A. G., Suijkerbuijk, K. P. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers-Sonderen, M. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., de Meza, M. M., Piersma, D., van Rijn, R. S., Stevense-den Boer, M. A. M., van der Veldt, A. A. M., Vreugdenhil, G., Wouters, M. W. J. M., Franken, M., van Baal, P. H. M., and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Published
- 2022
37. Health state utilities of advanced melanoma patients treated in clinical practice in the era of novel immuno- and targeted therapies
- Author
-
Franken, M., de Groot, S., van Dongen, A., Leeneman, B., Groot, Uyl-De C. A., Aarts, M. J. B., Berkmortel, van den F. W. P. J., Blank, C. U., Boers-Sonderen, M. J., Van den Eertwegh, A. J. M., De Groot, J. W. B., Haanen, J. B. A. G., Hospers, G. A. P., Kapiteijn, E., van Not, O. J., Piersma, D., van Rijn, R. S., Boer, Stevense-den M. A. M., Suijkerbuijk, K. P. M., van der Veldt, A. A. M., Vreugdenhil, G., Wouters, M. W. J. M., Versteegh, M., Blommestein, H. M., Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Clinical Neuropsychology
- Published
- 2022
38. Quality of life in advanced melanoma patients in the era of novel immuno- and targeted therapies
- Author
-
Franken, M., Leeneman, B., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers-Sonderen, M. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Haanen, J. B. A. G., Hospers, G. A. P., Kapiteijn, E., van Not, O. J., Piersma, D., van Rijn, R. S., Stevense-den Boer, M. A. M., Suijkerbuijk, K. P. M., van der Veldt, A. A. M., Vreugdenhil, G., Wouters, M. W. J. M., van Dongen, A., Uyl-De Groot, C. A., and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Published
- 2022
39. Validity of the eq-5d-3l and eq-5d-5l in advanced melanoma
- Author
-
Franken, M., van Dongen, A., Leeneman, B., Groot, Uyl-De C. A., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers-Sonderen, M. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Haanen, J. B. A. G., Hospers, G. A. P., Kapiteijn, E., de Meza, M. M., Piersma, D., van Rijn, R. S., Boer, Stevense-den M. A. M., Suijkerbuijk, K. P. M., van der Veldt, A. A. M., Vreugdenhil, G., Wouters, M. W. J. M., Blommestein, H. M., Versteegh, M., and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Published
- 2022
40. P71 The Development of a Flexible and Easy to Tailor Disease Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma by Combining Trial and Real-World Data
- Author
-
de Groot, S, primary, Blommestein, HM, additional, Leeneman, B, additional, Uyl-De, Groot CA, additional, Haanen, JBAG, additional, Suijkerbuijk, KPM, additional, Aarts, M.J.B., additional, van den Berkmortel, FWPJ, additional, Blank, CU, additional, Boers-Sonderen, MJ, additional, van den Eertwegh, AJM, additional, de Groot, JWB, additional, Hospers, GAP, additional, Kapiteijn, E, additional, de Meza, MM, additional, Piersma, D, additional, van Rijn, RS, additional, Stevense-den Boer, MAM, additional, van der Veldt, AAM, additional, Vreugdenhil, G, additional, Wouters, MWJM, additional, Franken, M, additional, and van Baal, PHM, additional
- Published
- 2022
- Full Text
- View/download PDF
41. POSC365 Health State Utilities of Advanced Melanoma Patients Treated in Clinical Practice in the Era of Novel Immuno- and Targeted Therapies
- Author
-
Franken, M, primary, de Groot, S, additional, van Dongen, A, additional, Leeneman, B, additional, Uyl-De Groot, CA, additional, Aarts, MJB, additional, van den Berkmortel, FWPJ, additional, Blank, CU, additional, Boers-Sonderen, MJ, additional, van den Eertwegh, AJM, additional, de Groot, JWB, additional, Haanen, JBAG, additional, Hospers, GAP, additional, Kapiteijn, E, additional, van Not, OJ, additional, Piersma, D, additional, van Rijn, RS, additional, Stevense-den Boer, MAM, additional, Suijkerbuijk, KPM, additional, van der Veldt, AAM, additional, Vreugdenhil, G, additional, Wouters, MWJM, additional, Versteegh, M, additional, and Blommestein, HM, additional
- Published
- 2022
- Full Text
- View/download PDF
42. POSB361 Quality of Life in Advanced Melanoma Patients in the Era of Novel Immuno- and Targeted Therapies
- Author
-
Franken, M, primary, Leeneman, B, additional, Aarts, M.J.B., additional, van den Berkmortel, FWPJ, additional, Blank, CU, additional, Boers-Sonderen, MJ, additional, van den Eertwegh, AJM, additional, de Groot, JWB, additional, Haanen, JBAG, additional, Hospers, GAP, additional, Kapiteijn, E, additional, van Not, OJ, additional, Piersma, D, additional, van Rijn, RS, additional, Stevense-den Boer, MAM, additional, Suijkerbuijk, KPM, additional, van der Veldt, AAM, additional, Vreugdenhil, G, additional, Wouters, MWJM, additional, van Dongen, A, additional, and Uyl-De Groot, CA, additional
- Published
- 2022
- Full Text
- View/download PDF
43. POSC366 Validity of the EQ-5D-3L and EQ-5D-5L in Advanced Melanoma
- Author
-
Franken, M, primary, van Dongen, A, additional, Leeneman, B, additional, Uyl-De Groot, CA, additional, Aarts, MJB, additional, van den Berkmortel, FWPJ, additional, Blank, CU, additional, Boers-Sonderen, MJ, additional, van den Eertwegh, AJM, additional, de Groot, JWB, additional, Haanen, JBAG, additional, Hospers, GAP, additional, Kapiteijn, E, additional, de Meza, MM, additional, Piersma, D, additional, van Rijn, RS, additional, Stevense-den Boer, MAM, additional, Suijkerbuijk, KPM, additional, van der Veldt, AAM, additional, Vreugdenhil, G, additional, Wouters, MWJM, additional, Blommestein, HM, additional, and Versteegh, M, additional
- Published
- 2022
- Full Text
- View/download PDF
44. Survival of stage IV melanoma in Belgium and the Netherlands
- Author
-
Suijkerbuijk, K.P.M., primary, Haanen, J.B.A.G., additional, Boers‐Sonderen, M.J., additional, Hospers, G.A.P., additional, Blank, C.U., additional, van den Berkmortel, F.W.P.J., additional, de Groot, J.W.B., additional, Piersma, D., additional, Aarts, M.J.B., additional, van Rijn, R.S., additional, Vreugdenhil, G., additional, Westgeest, H.M., additional, Kapiteijn, E., additional, van der Veldt, A.A.M., additional, and van den Eertwegh, A.J.M., additional
- Published
- 2021
- Full Text
- View/download PDF
45. 1081P Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands
- Author
-
Breeschoten, J.V., primary, Van den Eertwegh, A.J.M., additional, de Wreede, L., additional, Hilarius, D., additional, van Zwet, E., additional, Haanen, J.B.A.G., additional, Blank, C.U., additional, Aarts, M., additional, Van den Berkmortel, F., additional, de Groot, J.W.B., additional, Hospers, G.A., additional, Kapiteijn, E., additional, Piersma, D., additional, van Rijn, R.S., additional, Stevense, M., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Boers-Sonderen, M., additional, Suijkerbuijk, K., additional, and Wouters, M.W.J.M., additional
- Published
- 2021
- Full Text
- View/download PDF
46. 1070P Adjuvant treatment for melanoma in clinical practice: Trial versus reality
- Author
-
De Meza, M.M., primary, Ismail, R., additional, Blokx, W.A.M., additional, Blank, C.U., additional, Van den Eertwegh, A.J.M., additional, Aarts, M., additional, van Akkooi, A.C.J., additional, Van den Berkmortel, F., additional, Boers-Sonderen, M., additional, Kapiteijn, E., additional, de Groot, J.W.B., additional, Haanen, J.B.A.G., additional, Hospers, G.A., additional, Piersma, D., additional, van Rijn, R.S., additional, Van der Veldt, A.A.M., additional, Vreugdenhil, G., additional, Westgeest, H.M., additional, Suijkerbuijk, K., additional, and Wouters, M.W.J.M., additional
- Published
- 2021
- Full Text
- View/download PDF
47. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy
- Author
-
Verver, D., Grünhagen, D.J., Akkooi, A.C. van, Aarts, M.J., Berkmortel, F. van den, Eertwegh, A.J. van den, Groot, J.W.B. de, Boers-Sonderen, M.J., Haanen, J., Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Tije, A.J. Ten, Vreugdenhil, G., Verhoef, C., Veldt, A.A.M. van der, Verver, D., Grünhagen, D.J., Akkooi, A.C. van, Aarts, M.J., Berkmortel, F. van den, Eertwegh, A.J. van den, Groot, J.W.B. de, Boers-Sonderen, M.J., Haanen, J., Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Tije, A.J. Ten, Vreugdenhil, G., Verhoef, C., and Veldt, A.A.M. van der
- Abstract
Contains fulltext : 244571.pdf (Publisher’s version ) (Open Access), Melanoma of unknown primary (MUP) is considered different from melanoma of known primary (MKP), and it is unclear whether these patients benefit equally from novel therapies. In the current study, characteristics and overall survival (OS) of patients with advanced and metastatic MUP and MKP were compared in the era of novel therapy. Patients were selected from the prospective nation-wide Dutch Melanoma Treatment Registry (DMTR). The following criteria were applied: diagnosis of stage IIIc unresectable or IV cutaneous MKP (cMKP) or MUP between July 2012 and July 2017 and treatment with immune checkpoint inhibition and/or targeted therapy. OS was estimated using the Kaplan-Meier method. The stratified multivariable Cox regression model was used for adjusted analysis. A total of 2706 patients were eligible including 2321 (85.8%) patients with cMKP and 385 (14.2%) with MUP. In comparative analysis, MUP patients more often presented with advanced and metastatic disease at primary diagnosis with poorer performance status, higher LDH, and central nervous system metastases. In crude analysis, median OS of cMKP or MUP patients was 12 months (interquartile range [IQR] 5 - 44) and 14 months (IQR 5 - not reached), respectively (P = 0.278). In adjusted analysis, OS in MUP patients was superior (hazard rate 0.70, 95% confidence interval 0.58-0.85; P < 0.001). As compared to patients with advanced and metastatic cMKP, MUP patients have superior survival in adjusted analysis, but usually present with poorer prognostic characteristics. In crude analysis, OS was comparable indicating that patients with MUP benefit at least equally from treatment with novel therapies.
- Published
- 2021
48. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients
- Author
-
Biewenga, M., Kooij, M.K. van der, Wouters, M., Aarts, M.J., Berkmortel, F. van den, Groot, J.W.B. de, Boers-Sonderen, M.J., Hospers, G.A., Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Tije, A.J. Ten, Veldt, A.A.M. van der, Vreugdenhil, G., Haanen, J., Eertwegh, A.J. van den, Hoek, B. van, Kapiteijn, E., Biewenga, M., Kooij, M.K. van der, Wouters, M., Aarts, M.J., Berkmortel, F. van den, Groot, J.W.B. de, Boers-Sonderen, M.J., Hospers, G.A., Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Tije, A.J. Ten, Veldt, A.A.M. van der, Vreugdenhil, G., Haanen, J., Eertwegh, A.J. van den, Hoek, B. van, and Kapiteijn, E.
- Abstract
Item does not contain fulltext, BACKGROUND: Checkpoint inhibitor-induced hepatitis is an immune-related adverse event of programmed cell death protein 1 (PD-1) inhibition, cytotoxic T-lymphocyte associated 4 (CTLA-4) inhibition or the combination of both. Aim of this study was to assess whether checkpoint inhibitor-induced hepatitis is related to liver metastasis and outcome in a real-world nationwide cohort. METHODS: Data from the prospective nationwide Dutch Melanoma Treatment Registry (DMTR) was used to analyze incidence, risk factors of checkpoint inhibitor-induced grade 3-4 hepatitis and outcome. RESULTS: 2561 advanced cutaneous melanoma patients received 3111 treatments with checkpoint inhibitors between May 2012 and January 2019. Severe hepatitis occurred in 30/1620 (1.8%) patients treated with PD-1 inhibitors, in 29/1105 (2.6%) patients treated with ipilimumab and in 80/386 (20.7%) patients treated with combination therapy. Patients with hepatitis had a similar prevalence of liver metastasis compared to patients without hepatitis (32% vs. 27%; p = 0.58 for PD-1 inhibitors; 42% vs. 29%; p = 0.16 for ipilimumab; 38% vs. 43%; p = 0.50 for combination therapy). There was no difference in median progression free and overall survival between patients with and without hepatitis (6.0 months vs. 5.4 months progression-free survival; p = 0.61; 17.0 vs. 16.2 months overall survival; p = 0.44). CONCLUSION: Incidence of hepatitis in a real-world cohort is 1.8% for PD-1 inhibitor, 2.6% for ipilimumab and 20.7% for combination therapy. Checkpoint inhibitor-induced hepatitis had no relation with liver metastasis and had no negative effect on the outcome.
- Published
- 2021
49. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis
- Author
-
Breeschoten, J. van, Wouters, M., Hilarius, D.L., Haanen, J.B.A.G., Blank, C.U., Aarts, M.J., Berkmortel, F. van den, Groot, J.B. de, Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Blokx, W.A.M., Tije, B.J. Ten, Veldt, A., Vreugdenhil, A., Boers-Sonderen, M.J., Eertwegh, A.J. van den, Breeschoten, J. van, Wouters, M., Hilarius, D.L., Haanen, J.B.A.G., Blank, C.U., Aarts, M.J., Berkmortel, F. van den, Groot, J.B. de, Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Blokx, W.A.M., Tije, B.J. Ten, Veldt, A., Vreugdenhil, A., Boers-Sonderen, M.J., and Eertwegh, A.J. van den
- Abstract
Contains fulltext : 232046.pdf (Publisher’s version ) (Closed access), BACKGROUND: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of BRAF(V600)-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of this study was to use propensity score matching to compare first-line anti-PD-1 monotherapy vs. BRAF/MEK inhibitors in advanced BRAF(V600)-mutant melanoma patients. METHODS: We selected patients diagnosed between 2014 and 2017 with advanced melanoma and a known BRAF(V600)-mutation treated with first-line BRAF/MEK inhibitors or anti-PD-1 antibodies, registered in the Dutch Melanoma Treatment Registry. Patients were matched based on their propensity scores using the nearest neighbour and the optimal matching method. RESULTS: Between 2014 and 2017, a total of 330 and 254 advanced melanoma patients received BRAF/MEK inhibitors and anti-PD-1 monotherapy as first-line systemic therapy. In the matched cohort, patients receiving anti-PD-1 antibodies as a first-line treatment had a higher median and 2-year overall survival compared to patients treated with first-line BRAF/MEK inhibitors, 42.3 months (95% CI: 37.3-NE) vs. 19.8 months (95% CI: 16.7-24.3) and 65.4% (95% CI: 58.1-73.6) vs. 41.7% (95% CI: 34.2-51.0). CONCLUSIONS: Our data suggest that in the matched BRAF(V600)-mutant advanced melanoma patients, anti-PD-1 monotherapy is the preferred first-line treatment in patients with relatively favourable patient and tumour characteristics.
- Published
- 2021
50. Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases
- Author
-
Ismail, R.K., Sikkes, N.O., Wouters, M., Hilarius, D.L., Pasmooij, A.M., Eertwegh, A.J. van den, Aarts, M.J., Berkmortel, F. van den, Boers-Sonderen, M.J., Groot, J.W.B. de, Haanen, J., Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Tije, B.J. Ten, Veldt, A.A.M. van der, Vreugdenhil, A., Dartel, M. van, Boer, A. de, Ismail, R.K., Sikkes, N.O., Wouters, M., Hilarius, D.L., Pasmooij, A.M., Eertwegh, A.J. van den, Aarts, M.J., Berkmortel, F. van den, Boers-Sonderen, M.J., Groot, J.W.B. de, Haanen, J., Hospers, G.A., Kapiteijn, E., Piersma, D., Rijn, R.S. van, Suijkerbuijk, K.P., Tije, B.J. Ten, Veldt, A.A.M. van der, Vreugdenhil, A., Dartel, M. van, and Boer, A. de
- Abstract
Contains fulltext : 232080.pdf (Publisher’s version ) (Open Access), Postapproval trials and patient registries have their pros and cons in the generation of postapproval data. No direct comparison between clinical outcomes of these data sources currently exists for advanced melanoma patients. We aimed to investigate whether a patient registry can complement or even replace postapproval trials. Postapproval single-arm clinical trial data from the Medicines Evaluation Board and real-world data from the Dutch Melanoma Treatment Registry were used. The study population consisted of advanced melanoma patients with brain metastases treated with targeted therapies (BRAF- or BRAF-MEK inhibitors) in the first line. A Cox hazard regression model and a propensity score matching (PSM) model were used to compare the two patient populations. Compared to patients treated in postapproval trials (n = 467), real-world patients (n = 602) had significantly higher age, higher ECOG performance status, more often ≥3 organ involvement and more symptomatic brain metastases. Lactate dehydrogenase levels were similar between both groups. The unadjusted median overall survival (mOS) in postapproval clinical trial patients was 8.7 (95% CI, 8.1-10.4) months compared to 7.2 (95% CI, 6.5-7.7) months (P < 0.01) in real-world patients. With the Cox hazard regression model, survival was adjusted for prognostic factors, which led to a statistically insignificant difference in mOS for trial and real-world patients of 8.7 (95% CI, 7.9-10.4) months compared to 7.3 (95% CI, 6.3-7.9) months, respectively. The PSM model resulted in 310 matched patients with similar survival (P = 0.9). Clinical outcomes of both data sources were similar. Registries could be a complementary data source to postapproval clinical trials to establish information on clinical outcomes in specific subpopulations.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.